The central role of thrombin in the initiation and propagation of intravascular thrombus provides a strong rationale for direct thrombin inhibitors in acute coronary syndromes (ACS). Direct thrombin inhibitors are theoretically likely to be more effective than indirect thrombin inhibitors, such as unfractionated heparin or low-molecular-weight heparin, because the heparins block only circulating thrombin, whereas direct thrombin inhibitors block both circulating and clot-bound thrombin. Several initial phase 3 trials did not demonstrate a convincing benefit of direct thrombin inhibitors over unfractionated heparin. However, the Direct Thrombin Inhibitor Trialists' Collaboration meta-analysis confirms the superiority of direct thrombin inhibitors, particularly hirudin and bivalirudin, over unfractionated heparin for the prevention of death or myocardial infarction (MI) during treatment in patients with ACS, primarily due to a reduction in MI (odds ratio, 0.80; 95% confidence interval, 0.70 to 0.91) with little impact on death. The absolute risk reduction in the composite of death or MI at the end of treatment (0.8%) was similar at 30 days (0.7%), indicating no loss of benefit after cessation of therapy. Supportive evidence for the superiority of direct thrombin inhibitors over heparin derives from the recently reported Hirulog and Early Reperfusion or Occlusion (HERO)-2 randomized trial with ST-segment elevation ACS, which demonstrated a similar benefit of bivalirudin over heparin for the prevention of death or MI at 30 days (absolute risk reduction 1.0%), again primarily due to a reduction in MI during treatment (odds ratio, 0.70; 95% confidence interval, 0.56 to 0.87), with little impact on death. Further evaluation of hirudin and bivalirudin in the antithrombotic management of patients with ACS is warranted. (J Am Coll Cardiol 2003;41:70S-78S)
The central role of thrombin in the initiation and propagation of intravascular thrombus provides a strong rationale for direct thrombin inhibitors in acute coronary syndromes (ACS). Direct thrombin inhibitors are theoretically likely to be more effective than indirect thrombin inhibitors, such as unfractionated heparin or low-molecular-weight heparin, because the heparins block only circulating thrombin, whereas direct thrombin inhibitors block both circulating and clot-bound thrombin. Several initial phase 3 trials did not demonstrate a convincing benefit of direct thrombin inhibitors over unfractionated heparin. However, the Direct Thrombin Inhibitor Trialists' Collaboration meta-analysis confirms the superiority of direct thrombin inhibitors, particularly hirudin and bivalirudin, over unfractionated heparin for the prevention of death or myocardial infarction (MI) during treatment in patients with ACS, primarily due to a reduction in MI (odds ratio, 0.80; 95% confidence interval, 0.70 to 0.91) with little impact on death. The absolute risk reduction in the composite of death or MI at the end of treatment (0.8%) was similar at 30 days (0.7%), indicating no loss of benefit after cessation of therapy. Supportive evidence for the superiority of direct thrombin inhibitors over heparin derives from the recently reported Hirulog and Early Reperfusion or Occlusion (HERO)-2 randomized trial with ST-segment elevation ACS, which demonstrated a similar benefit of bivalirudin over heparin for the prevention of death or MI at 30 days (absolute risk reduction 1.0%), again primarily due to a reduction in MI during treatment (odds ratio, 0.70; 95% confidence interval, 0.56 to 0.87), with little impact on death. The most common underlying pathophysiologic process in patients with non-ST-segment elevation acute coronary syndromes (ACS) involves the formation of nonocclusive thrombus at the site of vessel wall injury (1, 2) . Spontaneous or mechanical disruption of atherosclerotic plaque exposes thrombogenic material within the plaque to the blood, which leads to platelet adhesion and aggregation, coagulation activation, and thrombin generation (3) . Thrombin plays a central role in the process of thrombus formation, converting fibrinogen to fibrin, activating platelets, and recruiting additional platelets into the platelet-rich thrombus. The resulting intracoronary thrombus reduces myocardial perfusion and leads to unstable angina or acute myocardial infarction (MI).
Recognition of the pivotal role of thrombin in the initiation and propagation of intracoronary thrombus formation has led to intensive efforts to develop new therapies that block thrombin generation or activity (4). Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) indirectly inhibit thrombin through an antithrombin-dependent mechanism and are widely used in the management of arterial and venous thrombosis. In aspirin-treated patients with non-ST-segment elevation ACS, the addition of heparin is associated with a 30% reduction in the risk of recurrent MI or death during the first week (5) . An important limitation of heparin, however, is its inability to inhibit clot-bound thrombin (Fig. 1) . When thrombin is bound to fibrin, to soluble fibrin degradation products, or to exposed subendothelial matrix proteins, it is protected from inactivation by heparin but remains enzymatically active. In such a scenario, thrombin is able to amplify its own generation through a positive feedback loop via coagulation factors V and VIII, thereby continuing to promote thrombus formation (6, 7) .
Direct thrombin inhibitors have important biologic and pharmacokinetic advantages over heparins (Table 1) (8) . Direct thrombin inhibitors are able to specifically block both fluid-phase and tissue-bound thrombin and, therefore, reduce thrombin activity more effectively than UFH and LMWH (Fig. 1 ). Because they do not bind to plasma proteins and are not inactivated by heparinases, direct thrombin inhibitors also produce a more predictable anticoagulant response than UFH. Experimental results have shown that direct thrombin inhibitors are highly effective in the prevention of thrombus formation in models of arterial thrombosis (9,10). The accumulating evidence has led to a large number of clinical trials of direct thrombin inhibitors in patients with ACS (11).
The objectives of this paper are twofold: 1) to review the results of randomized clinical trials of direct thrombin inhibitors compared with UFH in patients with ACS overall, and subdivided, according to the absence or presence of persistent ST-segment elevation on the presentation electrocardiogram; and 2) to discuss the current role of direct thrombin inhibitors for the management of patients with ACS in the context of emerging anticoagulant and antiplatelet therapies, particularly glycoprotein (GP) IIb/ IIIa inhibitors.
DIRECT THROMBIN INHIBITORS
The prototype direct thrombin inhibitor is hirudin, a naturally occurring 65-amino acid polypeptide first isolated from the salivary gland of medicinal leeches and now available through recombinant DNA technology (12) . Many other direct thrombin inhibitor preparations have been developed, but only those that have been evaluated in patients with ACS are listed in Table 2 .
Hirudin is a potent and almost irreversible inhibitor of thrombin, blocking the active catalytic site as well as the substrate recognition exosite (13) . It has a half-life of approximately 60 min after intravenous administration and is primarily excreted through the kidneys, which may lead to its accumulation in patients with renal impairment. A polyethylene glycol-complexed preparation, PEG-hirudin, with an extended half-life, has also been developed.
Bivalirudin is a 20-amino acid polypeptide that was synthesized by linking an active site-directed, short-peptide chain to an analogue of the carboxy-terminal of hirudin (14) . Consequently, bivalirudin, like hirudin, is able to form a bivalent complex with thrombin, blocking both the active site and the substrate recognition exosite. However, it has a substantially shorter plasma half-life of 20 to 25 min because of cleavage by thrombin of the active site-binding peptide. This may provide two important advantages to bivalirudin. First, it may grant a safety advantage for bivalirudin over hirudin by allowing earlier re-exposure of the active site of thrombin, permitting hemostasis to occur. Second, it may confer an efficacy advantage by allowing thrombin activation of the natural anticoagulant, protein C (15). Bivalirudin is excreted primarily via nonrenal mechanisms.
Several synthetic univalent direct thrombin inhibitors have been evaluated in phase 1 and 2 ACS trials, including the noncovalent inhibitors argatroban and inogatran and the reversible covalent inhibitor efegatran (16 -18) . These agents target only the active site of thrombin, have a short half-life, and appear to be more potent inhibitors of fibrinbound thrombin than the bivalent inhibitors hirudin and bivalirudin (6, 19) .
RANDOMIZED DIRECT THROMBIN INHIBITOR TRIALS IN ACS
Major phase 3 randomized trials that have been performed in patients with ACS are summarized in Tables 3 and 4 . Hirudin. Initial studies demonstrating the feasibility of hirudin as an anticoagulant in patients with stable or unstable coronary disease (20 -23) were followed by phase 2 heparin-controlled trials in patients with ACS based on angiographic or clinical outcomes (24 -29) . Several angiographic studies demonstrated improvements in coronary artery patency with hirudin compared with heparin (24 -26) , while the initial clinical trials revealed promising reductions in important clinical outcomes during treatment (27) (28) (29) . These results prompted several study groups to initiate a series of major phase 3, randomized, heparincontrolled, direct thrombin inhibitor trials in ACS, including the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO), Hirudin for Improvement of Thrombolysis (HIT), Thrombolysis In Myocardial Infarction (TIMI), Organization to Assess Strategies for Ischemic Syndromes Figure 1 . Schematic demonstrating the antithrombin activity of heparin compared with direct thrombin inhibitors. Both heparin and direct thrombin inhibitors block circulating thrombin, but only direct thrombin inhibitors block tissue-bound thrombin. Tissue-bound thrombin remains enzymatically active, promoting further platelet and coagulation activation and thrombin generation. Three trials (GUSTO-2A, TIMI-9A, and HIT-3) were stopped due to excessive bleeding. In GUSTO-2A (30), investigators randomized ACS patients to a 72-to 120-h infusion of either hirudin (0.6 mg/kg bolus, 0.2 mg/kg/h infusion) or UFH, with a target activated partial thromboplastin time (aPPT) of 60 to 90 s for UFH and no dose adjustment for hirudin. Excessive intracranial bleeding occurred primarily in patients receiving thrombolytic therapy (incidence 1.8%) with only 0.3% occurring in the non-STsegment elevation ACS group.
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The TIMI-9A trial (31) randomly assigned patients with ST-segment elevation ACS receiving thrombolytic therapy to 96 h of treatment with hirudin (0.6 mg/kg bolus, 0.2 mg/kg/h infusion) or UFH. The Data and Safety Monitoring Board terminated the trial prematurely because of a high rate of hemorrhagic complications in both treatment groups, particularly in the hirudin group.
In the HIT-3 study (32), patients were randomized to 48 to 72 h of either hirudin (0.4 mg/kg bolus, 0.15 mg/kg/h infusion) or heparin as an adjunct to tissue plasminogen activator. The dose of both hirudin and UFH was adjusted during infusion to a target aPTT ratio of 2.0 to 3.5. The trial was terminated early because of an excess of intracranial bleeds in patients receiving hirudin (3.4% vs. 0%, p ϭ NS).
The GUSTO-2B (33) and TIMI-9B (34) trials were subsequently recommenced with lower doses of both hirudin (0.1 mg/kg bolus, 0.1 mg/kg/h infusion) and UFH, with a target aPTT of 60 to 85 s and 55 to 85 s, respectively. The projected recruitment was successfully achieved in both studies. In the GUSTO-2B trial at 30 days there was a borderline significant reduction in the primary composite outcome of death or MI with hirudin compared with UFH (odds ratio [OR], 0.89; 95% confidence interval [CI], 0.79 to 1.00), with consistent results when compared as an adjunct to thrombolysis or in non-ST-segment elevation ACS. In the TIMI-9B trial there was no benefit of hirudin over UFH at 30 days, either on the primary composite outcome of death, MI, cardiac failure, or cardiogenic shock or the composite of death or MI. However, there was a trend to reduction in nonfatal MI both during hospitalization and at 30 days. Neither GUSTO-2B nor TIMI-9B demonstrated an excess of major or intracranial bleeding with hirudin compared with heparin.
The OASIS-2 trial (35) randomized 10,141 patients with non-ST-segment elevation ACS to a 72-h infusion of hirudin (0.4 mg/kg bolus, 0.15 mg/kg/h infusion) or UFH, with a target aPTT of 60 to 100 s. This study demonstrated a nonsignificant difference between hirudin and heparin in the primary outcome of cardiovascular death or MI at seven days (3.6% vs. 4.2%). However, at the completion of study drug infusion, there was a significant reduction in cardiovascular death or MI with hirudin relative to heparin (2.0% vs. 2.6%). Compared with UFH, hirudin was associated with a significantly increased risk of major bleeding (1.2% vs. 0.7%), but not life-threatening bleeding (0.4% vs. 0.4%). There were no cases of intracranial bleeding during study drug infusion with hirudin and one case with UFH.
A pooled analysis of the OASIS, GUSTO-2B, and TIMI-9B trials confirms the superiority of hirudin compared with heparin for the prevention of death or MI at the completion of treatment (relative risk [RR], 0.78; p ϭ 0.0004), 7 days (RR, 0.84; p ϭ 0.002), and 30 to 35 days (RR, 0.90; p ϭ 0.016) (35). . This meta-analysis also included data from the prematurely terminated (for "business" reasons by the sponsors) phase 3 TIMI-8 trial that compared a 72-h infusion of bivalirudin with heparin in patients with non-ST-segment elevation ACS (target enrolment 5,320). Although only 133 patients were randomized before study termination, there was already a highly promising reduction in the risk of death or MI with bivalirudin compared with UFH at 14 days (2.9% vs. 9.2%) (44) .
Further evidence of the superiority of bivalirudin over heparin in ACS derives from the recently completed HERO-2 study (45) . This trial randomized 17,073 patients with acute MI receiving thrombolytic therapy to a 48-h infusion of bivalirudin or heparin. In order to test the hypothesis that exposure of tissue-bound thrombin by thrombolytic therapy is an important trigger for recurrent ischemic events, bivalirudin and heparin were administered before thrombolytic therapy. In the absence of major bleeding, dose reduction of bivalirudin was not allowed after 12 h 
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Direct Thrombin Inhibitors unless the aPTT was Ͼ150 s, or after 24 h unless the aPTT was Ͼ120 s.
The HERO-2 study demonstrated no difference in the primary outcome of death at 30 days in patients treated with bivalirudin compared with heparin. There was, however, an 8% reduction in the composite of death or MI at 30 days and a 30% reduction in the incidence of new MI at 96 h, a benefit that was maintained to 30 days. Modest excess bleeding occurred with bivalirudin compared with heparin (1.4% vs. 1.1%) with a similar trend for severe excess bleeding (0.7% vs. 0.5%, p ϭ 0.07). This was somewhat unexpected in view of the reduced risk of bleeding seen in earlier studies performed with this agent, but may be due to the higher aPTT levels at 12 h (median aPPT, 108 vs. 77 s; p Ͻ 0.0001) and 24 h (median aPPT, 80 vs. 57 s; p Ͻ 0.0001) in patients receiving bivalirudin compared with heparin. However, the incidence of moderate (major) and intracranial hemorrhage in this trial remained low compared with contemporary thrombolysis trials in patients with ACS, and the composite net clinical benefit outcome of death, MI, and nonfatal disabling stroke at 30 days favored bivalirudin (p ϭ 0.049). Univalent direct thrombin inhibitors. There has been only limited evaluation of univalent direct thrombin inhibitors in ACS, and the results have largely been disappointing. Although these agents were generally well tolerated with no excess major bleeding compared with heparin, most of the phase 2 trials were unable to demonstrate superiority of argatroban, efegatran, or inogatran compared with heparin, based on surrogate (angiographic, electrocardiographic) or clinical outcomes. In some cases the results suggested that they may be inferior (46 -49) .
DIRECT THROMBIN INHIBITOR TRIALISTS' COLLABORATION META-ANALYSIS
Despite several large, randomized trials, there has been uncertainty regarding the clinical benefit of direct thrombin inhibitors compared with heparin in patients with ACS, whether early treatment benefits are maintained long-term, and whether excess bleeding offsets any benefit of these agents. The reasons for this uncertainty include the possibility that direct thrombin inhibitors are not superior to UFH. Alternatively, the benefits may be modest, and larger trials than those conducted may be needed. Further, several of the trials may have chosen to measure the outcome several days or weeks after cessation of treatments, so that any real benefit may have been "diluted" by events occurring subsequent to treatment cessation.
To address these issues, the Direct Thrombin Inhibitor Trialists' Collaboration recently reported the results of a systematic review of major randomized trials of direct thrombin inhibitors compared with UFH in patients with unstable coronary disease (11, 50) . Trials included in the meta-analysis had to randomize patients with ACS or patients undergoing percutaneous coronary intervention, compare a direct thrombin inhibitor with heparin, and record data on the key irreversible outcomes of death and MI. The primary outcome was the composite of death or MI at the end of treatment when the maximal benefit of antithrombotic therapy is likely to be evident. Outcomes at day 7 and day 30 also were examined. Small trials (Ͻ200 patients or Ͻ100 controls) and trials performed with excessive doses of direct thrombin inhibitor or heparin (TIMI-9A, GUSTO-2A, HIT-3) were not included.
Overall, there was a 15% reduction in death or MI at the end of treatment with direct thrombin inhibitors compared with heparin (4.3% vs. 5.1%; OR, 0.85; 95% CI, 0.77 to 0.94; p ϭ 0.001), equivalent to preventing eight events for every 1,000 patients treated (50) ( Table 5 ). This absolute reduction in death or MI was maintained to 30 days (Table  6) . A similar benefit was evident in all categories of trials, including ACS, and subdivided according to ST-segment elevation or non-ST-segment elevation ( Table 5 ). The benefit was seen with hirudin (OR, 0.83; 95% CI, 0.74 to ACS ϭ acute coronary syndrome; CI ϭ confidence interval; DTI ϭ direct thrombin inhibitor; MI ϭ myocardial infarction; OR ϭ odds ratio.
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0.92) and bivalirudin (OR, 0.53; 95% CI, 0.24 to 1.17) but not univalent thrombin inhibitors (OR, 1.35; 95% CI, 0.89 to 2.05). The greatest benefit of direct thrombin inhibitors compared with heparin appeared to be in patients undergoing percutaneous coronary intervention during study infusion, where there was a 32% reduction in death or MI (4.6% vs. 6.6%; OR, 0.68; 95% CI, 0.57 to 0.83).
Although direct thrombin inhibitors compared with heparin were not associated with an overall excess of major bleeding or intracranial bleeding in the ACS trials, pooled results from all the trials (including percutaneous coronary intervention trials) demonstrated that hirudin was associated with an increased risk of major bleeding (1.7% vs. 1.3%; OR, 1.28; 95% CI, 1.06 to 1.55), while both bivalirudin (4.2% vs. 9.0%; OR, 0.44; 95% CI, 0.34 to 0.56) and univalent inhibitors (0.7% vs. 1.3%; OR, 0.55; 95% CI, 0.25 to 1.20) were associated with a reduced risk of major bleeding. The shorter half-life and a more transient inhibition of the active site of thrombin may account for the reduced risk of major bleeding associated with bivalirudin compared with hirudin (51), although this was not confirmed in the HERO-2 trial (45).
CURRENT ROLES AND FUTURE DIRECTIONS OF DIRECT THROMBIN INHIBITORS IN ACS
The consistent results of the HERO-2 trial (45), hirudin (35) and bivalirudin (41) meta-analyses, and Direct Thrombin Inhibitor Trialists' Collaboration meta-analysis (50) provide clear evidence for the superiority of the direct thrombin inhibitors, particularly hirudin and bivalirudin, over heparin in ACS, with or without ST-segment elevation. Although the bulk of the randomized evidence in non-ST-segment elevation ACS derives from trials comparing hirudin with heparin, the consistency of the treatment effects of bivalirudin in patients with ST-segment elevation and undergoing percutaneous coronary intervention suggests that this agent is likely to be similarly effective in patients without ST-segment elevation. By contrast, there are currently no data supporting the use of univalent direct thrombin inhibitors in patients with ACS.
There are a number of unresolved issues. First, the greater efficacy of direct thrombin inhibitors in reducing death or MI in patients with ACS is balanced, in part, by an excess of major bleeding, particularly with hirudin, which may limit its use to patients at highest risk of future vascular events in whom the benefits are more likely to outweigh the bleeding risks. One such high-risk group may be patients with ACS undergoing percutaneous coronary intervention in whom both the relative and absolute benefits of hirudin in reducing death or MI appear to be greatest (50, 52) .
Second, available trials comparing hirudin with UFH in patients with ACS were largely performed before the widespread use of intravenous GP IIb/IIIa inhibitors. However, intravenous GP IIb/IIIa inhibitor agents appear to be beneficial only when administered in combination with heparin and compared against placebo (53) . Furthermore, indirect comparison of trials comparing the incremental benefit of direct thrombin inhibitors versus UFH, and GP IIb/IIIa inhibitors plus UFH, versus UFH alone, indicate a similar magnitude of benefit on end-of-treatment (RR reduction of 15% and 16%, respectively) and 30-day (RR reduction of 8% and 9%, respectively) outcomes of death and MI (Table 7 , Fig. 2 ). The reason for this may be that direct thrombin inhibitors have both anticoagulant and antiplatelet properties (54) , while GP IIb/IIIa inhibitors have only antiplatelet activity and require the addition of an anticoagulant, such as heparin, to block coagulation. This suggests a possible role for direct thrombin inhibitors as a single drug that replaces the combination of GP IIb/IIIa inhibitors and heparin in patients with ACS, particularly high-risk patients undergoing percutaneous coronary intervention. At least one study comparing bivalirudin with or without a GP IIb/IIIa inhibitor versus UFH plus a GP IIb/IIIa inhibitor (Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events [REPLACE] trial) is further testing this hypothesis (55). It is interesting to compare the development of the direct thrombin inhibitor and that of the intravenous GP IIb/IIIa inhibitors. The latter agents were initially tested in patients undergoing percutaneous coronary intervention (Evaluation of IIb/IIIa Platelet receptor antagonist 7E3 in preventing Ischemic Complications [EPIC]) (56), a scenario in which patients were treated before mechanical rupturing of plaques by balloon angioplasty. In EPIC, outcomes were measured relatively early (at 30 days), and the benefits of GP IIb/IIIa inhibitors compared with heparin were relatively large (RR reduction, 35%). Subsequent trials of GP IIb/IIIa inhibitors in ACS have shown much more modest benefits, especially when percutaneous coronary intervention rates were not high (53) . By contrast, although there was an early trial of direct thrombin inhibitors in percutaneous coronary intervention (Hirudin in a European restenosis prevention triaL VErsus heparin Treatment In PTCA patients [HEL-VETICA]) (57), outcomes were measured late (180 days). However, the 30-day outcomes for the prevention of the composite outcome of death or MI were similar in HEL-VETICA and EPIC (RR reduction of 39% and 35%, respectively). Most subsequent trials of direct thrombin inhibitors were in broad populations with ACS where the overall benefits, compared with heparin, are almost identical to the overall benefits of GP IIb/IIIa inhibitors versus placebo when added to heparin in patients with ACS (53) . These considerations raise the possibility that direct thrombin inhibitors (at least hirudin and bivalirudin) are similar in efficacy to GP IIb/IIIa inhibitors, and further suggest that the sequence and types of trials may have affected the perception of their efficacy. The REPLACE trial will be of great scientific and medical importance as it is likely to further clarify the relative "merits" of these two classes of agents. Finally, randomized trials of direct thrombin inhibitors in patients with non-ST-segment elevation ACS were performed before the widespread use of clopidogrel (58), LMWH (5), and third-generation fibrin-specific thrombolytic agents (59) . Further data are required to determine the efficacy and safety of direct thrombin inhibitors in the context of current antithrombotic strategies before they can be used in routine clinical practice in patients with ACS.
